| Abstrakt: |
A new study conducted by researchers at the National Cardiovascular Center in Jakarta, Indonesia compared the effectiveness of different ventricular assist devices (VADs) in treating heart failure patients. The study analyzed 49 studies involving 31,105 patients and found that the HeartMate III (HM3) device had the lowest risk of mortality, cerebrovascular accidents, other neurologic events, pump thrombosis, bleeding, and hospital admissions compared to the HeartMate II (HM2) and Heartware VADs (HVAD). The researchers recommend exchanging older VAD models for the HM3 device, but only if complications are present. The study was published in SAGE Open Medicine. [Extracted from the article] |
